By Paige Minemyer
UnitedHealth Group has topped the industry in profitability for the third straight quarter, according to company earnings reports.
read more
By Ben Adams
The biopharma industry has received acclaim during the COVID-19 pandemic. But while some companies have been working hard on life-saving therapies, others' actions have further stained the industry's already shaky reputation.
read more
By Kyle LaHucik
In its quest to revive a failed Taisho depression drug, Ancora Bio needed a leader with experience getting a therapy to market for the depression field. So, the Joe Jimenez-founded biotech has snagged Sage CMO Stephen Kanes, who secured the first FDA approval for a postpartum depression drug.
read more
By Anastassia Gliadkovskaya
Ovia Health, a family benefits solution, conducts monthly surveys of 4,500 users across each of its various apps on their attitudes toward the COVID-19 vaccine. Most remain hesitant, though most have discussed the benefits with their provider.
read more
By Nick Paul Taylor
GlaxoSmithKline has boosted its challenge for the anemia due to chronic kidney disease market, revealing a clean sweep of hits on key endpoints across two phase 3 clinical trials. But with the FDA rejecting AstraZeneca’s rival drug, doubts remain about GSK’s chances of getting to market.
read more
By Joseph Keenan
Samsung Pharm was hit with a three-month suspension of all manufacturing operations after Korea’s Ministry of Food and Drug Safety found the company was using one production manager to oversee operations at two separate facilities.
read more
By Dave Muoio
National Nurses United argued that Kaiser Permanente's cost-minded hospital-at-home programs limit the role of nurses and, subsequently, reduce the care patients receive. The system responded that the program does not compromise treatment and that hospital nurses "will continue to play a critically important and highly valued role."
read more
By Andrea Park
Three years after Alcon pulled its CyPass Micro-Stent from the market due to safety concerns, the Novartis spinoff has found another glaucoma treatment device to take its place.
read more
By Angus Liu
As the targeted treatment space for ALK-positive non-small cell lung cancer becomes more crowded, Takeda is trying to get ahead of the competition with a drug pricing tool that’s rarely used among U.S. oncology players.
read more
By Conor Hale
Following a multibillion-dollar acquisition late last year to grow its cardiac connected care franchise, Philips is continuing the effort with a new deal to take over Cardiologs, a French startup developing artificial-intelligence-powered diagnostics.
read more
By Andrea Park
The funding has been earmarked specifically for technological improvements to the NHS’ diagnostic services, with a goal of streamlining the entire process of ordering, performing and reviewing tests to detect and begin treating health conditions as early as possible.
read more
